1-4 of 4
Anita Mathias
Close
Sort by
Journal Articles

Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects

Brian J Kirby, Richard Aranda, Renee Ward, Marcos W Steinberg, Maria Hernandez, Judith Sosa, Matt Cravets, Mark J Rose, Robin Osterhout, Zhaoqing Ding, Isharat Yusuf, Judith Fox, Anita Mathias
Journal: Blood
Blood (2022) 140 (Supplement 1): 11570–11571.
https://doi.org/10.1182/blood-2022-160388
Published: 2022
Journal Articles

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Carole Soussain, Samar Issa, Katharine L Lewis, Christian Grommes, Judith Fox, Renee Ward, Caryn Peterson, Matt Cravets, Anita Mathias, Judith Sosa, Brian J Kirby, Zhaoqing Ding, Isharat Yusuf, Mark J Rose, Marcos W Steinberg, Han W. Tun
Journal: Blood
Blood (2022) 140 (Supplement 1): 12068–12069.
https://doi.org/10.1182/blood-2022-158599
Published: 2022
Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

Vinay Manu Daryani, PharmD, Shringi Sharma, PhD, Guan Xing, PhD, Jeffrey Silverman, PhD, Adeboye Henry Adewoye, MD, Anita Mathias, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5344.
https://doi.org/10.1182/blood.V130.Suppl_1.5344.5344
Published: 2017
Journal Articles

Exposure-Response of Entospletinib (ENTO) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Sneha Gupta, PhD, Amy Meng, PhD, Shringi Sharma, PhD, Wei Ye, PhD, Jeffrey Silverman, PhD, Esteban M. Abella, MD, Anita Mathias, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1735.
https://doi.org/10.1182/blood.V130.Suppl_1.1735.1735
Published: 2017